6:23 PM
 | 
Oct 28, 2009
 |  BC Extra  |  Company News

Ilaris approved in EU for CAPS

The EC approved an MAA for Ilaris canakinumab from Novartis AG (NYSE:NVS; SIX:NOVN) under exceptional circumstances to treat adults...

Read the full 83 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >